Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)

Study:

Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)

Rationale:

n/a

Purpose:

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.

Study Status: Recruiting

Recruiting:
Katie Gartner 216-445-1397 gartnek@ccf.org

Condition Intervention Phase
Eosinophilic Granulomatosis With Polyangiitis
Churg-Strauss Syndrome
n/a N/A

Verified by University of Pennsylvania November, 2013

Sponsored by: University of Pennsylvania
Information provided by: University of Pennsylvania
ClinicalTrials.gov identifier: NCT00315380

Study Type: Interventional

Study Design: Observational Model: Cohort, Time Perspective: Prospective

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Peter A. Merkel, MD, MPH., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site